[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-343313-105":3,"detail-sidebar-cat-0-en-105":80,"doc-detail-343313-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":73,"head_meta":75,"extra_data":77,"updated_unix":79},105,"en","structural-optimization-of-isoquinoline-derivatives-from-lycobetaine-and-their-inhibitory-activity-against-neuroendocrine-prostate-cancer-cells","Structural Optimization of Isoquinoline Derivatives from Lycobetaine and Their Inhibitory Activity against Neuroendocrine Prostate Cancer Cells","","Neuroendocrine prostate cancer (NEPC) is a highly aggressive, hormone-therapy-resistant malignancy with poor prognosis and limited options. Starting from the natural product lycobetaine, the lycobetaine scaffold was simplified to yield an isoquinoline derivative (compound 1) with aryl substitution at the 4-position and antiproliferative activity in LASCPC-01 cells. Through structural optimization and systematic SAR, compound 46 was identified, showing strong LASCPC-01 inhibition (IC50 0.47 µM) and >190-fold selectivity over PC-3. Mechanistic studies indicated G1 arrest and dose-dependent apoptosis. Compound 46 and lycobetaine produced different neuroendocrine marker responses, supporting a distinct antitumor mechanism.",{"@graph":14,"@context":72},[15,34,55],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/structural-optimization-of-isoquinoline-derivatives-from-lycobetaine-and-their-inhibitory-activity-against-neuroendocrine-prostate-cancer-cells/343313/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/structural-optimization-of-isoquinoline-derivatives-from-lycobetaine-and-their-inhibitory-activity-against-neuroendocrine-prostate-cancer-cells/343313.png","ImageObject",300,407,{"name":42,"@type":43},"Riley","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":33},"InteractionCounter",{"@type":54},"ViewAction",{"@type":56,"mainEntity":57},"FAQPage",[58,64,68],{"name":59,"@type":60,"acceptedAnswer":61},"Why is neuroendocrine prostate cancer (NEPC) clinically challenging?","Question",{"text":62,"@type":63},"NEPC is highly aggressive, resistant to hormone therapy, and associated with poor prognosis and limited therapeutic options.","Answer",{"name":65,"@type":60,"acceptedAnswer":66},"What was the role of lycobetaine in this study?",{"text":67,"@type":63},"Lycobetaine was used as the starting natural product, and its scaffold was simplified to generate an isoquinoline derivative (compound 1) for further optimization.",{"name":69,"@type":60,"acceptedAnswer":70},"How does compound 46 show improved anticancer performance compared with the parent compound?",{"text":71,"@type":63},"Compound 46 exhibits potent inhibitory activity against LASCPC-01 with an IC50 of 0.47 µM and high selectivity over PC-3, alongside dose-dependent induction of G1 arrest and apoptosis.","https://schema.org",{"og:url":32,"og:type":74,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":76,"canonical":32},"index,follow",{"doc_id":78,"site_id":7},343313,1790194663,{"code":4,"msg":81,"data":82},"success",[83,87,91,95,100,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":84,"show_sort_weight":85,"slug":86},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":88,"show_sort_weight":89,"slug":90},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":92,"show_sort_weight":93,"slug":94},"Exam",70,"exam",{"id":96,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},5,"Comic",60,"comic",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},6,"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":96,"slug":129},19,"General","general",{"code":4,"msg":81,"data":131},{"doc_id":78,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":33,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},1374391975076,"https://ap-avatar.wpscdn.com/avatar/14000253ca4ec9f6853?x-image-process=image/resize,m_fixed,w_180,h_180&k=1783305029341752051","molecules   \nArticle  \nStructural Optimization of Isoquinoline Derivatives from Lycobetaine and Their Inhibitory Activity against Neuroendocrine Prostate Cancer Cells  \nZhuo Zhang 1,†, Qianqian Shen 2, Yiyi Ji 3,†, Yanjie Ma 4,5, Haiyang Hou 2,6, Huajie Yang 4, Yinjie Zhu 3,*, Yi Chen 2,5 and Youhong Hu 1,4,5,6,7, *  \nCitation: Zhang, Z.; Shen, Q.; Ji, Y.; Ma, Y.; Hou, H.; Yang, H.; Zhu, Y.; Chen, Y.; Hu, Y. Structural Optimization of Isoquinoline Derivatives from Lycobetaine and Their Inhibitory Activity against Neuroendocrine Prostate Cancer Cells. Molecules 2024, 29, 4503. [https://](https://)[ ](https://)[doi.org/10.3390/molecules29184503](doi.org/10.3390/molecules29184503)  \nAcademic Editors: David Barker and Francisco Leon  \nReceived: 18 July 2024  \nRevised: 2 September 2024  \nAccepted: 13 September 2024  \nPublished: 23 September 2024  \nCopyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \n1 School of Chinese Materia Medica, College of Pharmacy, Nanjing University of Chinese Medicine, No. 138 Xianlin Road, Nanjing 210023, China; [s18-zhangzhuo@simm.ac.cn](s18-zhangzhuo@simm.ac.cn)  \n2 State Key Laboratory of Chemical Biology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China; [shenqianqian@simm.ac.cn](shenqianqian@simm.ac.cn) (Q.S.); [houhaiyang@simm.ac.cn](houhaiyang@simm.ac.cn) (H.H.); [ychen@simm.ac.cn](ychen@simm.ac.cn) (Y.C.)  \n3 Department of Urology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China; [jiyiyi@sjtu.edu.cn](jiyiyi@sjtu.edu.cn)  \n4 State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zu-ChongZhi Road, Shanghai 201203, China; [myj1007@simm.ac.cn](myj1007@simm.ac.cn) (Y.M.); [yanghuajie@simm.ac.cn](yanghuajie@simm.ac.cn) (H.Y.)  \n5 Shandong Laboratory of Yantai Drug Discovery, Bohai Rim Advanced Research Institute for Drug Discovery, Yantai 264117, China  \n6 University of Chinese Academy of Sciences, No. 19A Yuquan Road, Beijing 100049, China  \n7 School of Pharmaceutical Science and Technology, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, 1st Xiangshan Branch Alley, Hangzhou 310024, China  \n* [Correspondence: yinjiezhu@outlook.com](Correspondence: yinjiezhu@outlook.com) (Y.Z.); [yhhu@simm.ac.cn](yhhu@simm.ac.cn) (Y.H.)† These authors contributed equally to this work.  \nAbstract: Neuroendocrine prostate cancer (NEPC) is a highly aggressive cancer that is resistant to hormone therapy and characterized by poor prognosis, as well as limited therapeutic options. Since the natural product lycobetaine was reported to exhibit good antitumor activities against various types of cancers, we initially simplified the scaffold of lycobetaine to obtain the active compound 1, an isoquinoline derivative with an aryl moiety substitution at the 4-position, which showed apparent antiproliferative activities against NPEC cell line LASCPC-01 in vitro. Subsequently, we carried out structural optimization and systematic structure–activity relationship (SAR) studies on compound 1, leading to the discovery of compound 46, which demonstrated potent inhibitory activities against the LASCPC-01 cell line with an IC50 value of 0.47 µM. Moreover, compound 46 displayed remarkable selectivity over prostate cancer cell line PC-3 with a selectivity index greater than 190-fold. Further cell-based mechanism studies revealed that compound 46 and lycobetaine can effectively induce G1 cell cycle arrest and apoptosis dose dependently. However, lycobetaine inhibited the expression of neuroendocrine markers, while compound 46 slightly upregulated these proteins. This suggested","cbCaitonJaZWn2ML","https://ap.wps.com/l/cbCaitonJaZWn2ML","pdf",10941411,28,"English","# Introduction\n## Prostate cancer and NEPC background","[{\"question\":\"Why is neuroendocrine prostate cancer (NEPC) clinically challenging?\",\"answer\":\"NEPC is highly aggressive, resistant to hormone therapy, and associated with poor prognosis and limited therapeutic options.\"},{\"question\":\"What was the role of lycobetaine in this study?\",\"answer\":\"Lycobetaine was used as the starting natural product, and its scaffold was simplified to generate an isoquinoline derivative (compound 1) for further optimization.\"},{\"question\":\"How does compound 46 show improved anticancer performance compared with the parent compound?\",\"answer\":\"Compound 46 exhibits potent inhibitory activity against LASCPC-01 with an IC50 of 0.47 µM and high selectivity over PC-3, alongside dose-dependent induction of G1 arrest and apoptosis.\"}]","Structural Optimization of Isoquinoline Derivatives from Lycobetaine and Their Inhibitory Activity against Neuroendocrine Prostate Cancer Cells | PDF",1790050702,71,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a8709851229f959032a49662094046eb.webp",983,1390,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f46c7c3bbb900939f49661896020ff4c.webp",982,1388,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e61bbf28458c4a80b6fcdc0a29a63cc3.webp",981,1387,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cde9d5f119733a1a53dbc3502aa8fc43.webp",980,1385]